New trends in drug treatment of heart failure in old age

Submitted: 17 September 2018
Accepted: 16 November 2018
Published: 29 November 2018
Abstract Views: 1102
PDF: 557
HTML: 75
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Heart failure (HF) is a complex clinical syndrome, with high prevalence in the elderly. The World Heath Organization (WHO) predicts that by 2050 the population aged over 80 years will account around 400 million, reflecting that HF will still represent a major public health concern. Improved management of cardiovascular diseases and HF, together with the increased life expectancy explains, at least in part, the high prevalence of HF especially in the elderly. Beside the canonical therapy for HF failure, including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and aldosterone antagonists, new potential and promising therapies, such as sacubitril/valsartan, iron deficiency treatment and serelaxine, are emerging also in elderly HF patients. In this review we focus on the classical recommended HF therapy and the possible application of new trends in elderly.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Komici, K., Bencivenga, L., Spezzano, A., Nocella, P., Corbi, G., Ferrara, N., & Rengo, G. (2018). New trends in drug treatment of heart failure in old age. Geriatric Care, 4(4). https://doi.org/10.4081/gc.2018.7833

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.